Every Form 4 that Aeluma, Inc. (ALMU) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALMU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALMU filings page.
Aeluma, Inc. Chief Financial Officer Christopher P. Stewart reported 5,697 shares of common stock delivered or withheld for payment of exercise price or tax liability on September 30, 2026, at a reported price of $12.36 per share. His reported direct post-transaction amount was 67,781 shares, including 41,250 additional shares issuable upon vesting and settlement of existing RSUs previously reported in Table II.
Aeluma, Inc. Chief Financial Officer Stewart Christopher P. reported equity awards on September 21, 2026: 15,886 restricted stock units, 4,042 shares as a stock award in lieu of a cash bonus, and options covering 37,568 shares at a $13.61 exercise price. The RSUs are scheduled to vest and settle 25% on September 30, 2027, then in 12 quarterly increments. The options vest 25% on the first grant anniversary, then in 36 monthly increments. Separately, 1,450 shares were delivered or withheld for payment of exercise price or tax liability.
Aeluma, Inc. CEO and director Jonathan Klamkin reported the sale of 100,000 shares held through a Family Trust on September 21, 2026, at a weighted average $13.3532 per share; the sale was under a Rule 10b5-1 plan adopted May 23, 2026. The trust held 1,226,995 shares after the sale. Klamkin also received 31,771 RSUs, 12,675 shares as a stock award in lieu of a cash bonus, and 75,135 options with a $13.61 exercise price. Separately, 4,547 shares were delivered or withheld for payment of exercise price or tax liability at $13.61 per share.
Aeluma, Inc. director Byron Michael exercised 25,000 fully vested stock options on September 21, 2026, at an exercise price of $5.93 per share, acquiring 25,000 common shares. After the transaction, his reported holdings were 38,343 common shares and 20,833 stock options. No Rule 10b5-1 plan is reported.
Aeluma, Inc. (ALMU) director Steven Denbaars reported amended insider sales of common stock. He sold 12,500 shares on 2026-08-26 at a weighted average price of $13.8435 per share and another 12,500 shares on 2026-08-27 at a weighted average price of $13.8158 per share. Both transactions were effected under a Rule 10b5-1 trading plan adopted on November 20, 2025. The amendment states it was filed solely to include previously omitted details of this trading plan.
Aeluma, Inc. (ALMU) director Steven Denbaars reported two open-market sales of common stock. He sold 12,500 shares on August 26, 2026 at a weighted average price of $13.8435 per share and 12,500 shares on August 27, 2026 at a weighted average price of $13.8158, in multiple trades within the disclosed price ranges.
Aeluma, Inc. director and Chief Executive Officer Jonathan Klamkin reported several transactions in common stock on August 3, 2026. He recorded bona fide gifts totaling 40,000 shares, including a 20,000-share disposition of shares held indirectly through a family trust and a 20,000-share acquisition into direct ownership. He also sold 20,000 shares in open-market or private transactions under a Rule 10b5-1 trading plan adopted on December 3, 2025, consisting of 4,190 shares at a weighted-average price of $16.2918 per share (range $15.62–$16.61) and 15,810 shares at $16.8487 per share (range $16.62–$17.53).
Aeluma, Inc. reports that CEO Jonathan Klamkin executed multiple common stock transactions on July 1, 2026. One bona fide gift disposition moved 20,000 shares held indirectly by a family trust, and a separate gift transaction recorded acquisition of 20,000 shares into his direct ownership.
He then sold 19,900 shares at a weighted average price of $21.081 per share in transactions priced between $20.54 and $21.52, plus an additional 100 shares at $21.56, in open market or private transactions. After these trades, he holds 2,403 shares of Aeluma common stock directly. Footnotes explain that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2025.
Aeluma, Inc. Chief Executive Officer Jonathan Klamkin reported multiple insider transactions in the company’s common stock. On June 1, 2026, he sold a total of 20,000 shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025.
The sales were executed in several tranches at weighted average prices of $22.19, $23.32, $24.39, $25.12 and $26.25 per share. He also made bona fide gifts totaling 40,000 shares, including 20,000 shares from his direct holdings and 20,000 shares from an indirect position held by a family trust.
Following these transactions, Klamkin directly holds 22,403 shares of Aeluma common stock and indirectly holds 1,366,995 shares through a family trust.
Aeluma, Inc. director Steven Denbaars reported open-market sales of 25,000 shares of Common Stock. The sales occurred on May 19–20, 2026 at weighted average prices ranging from about $19.56 to $21.30 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 20, 2025. Following these transactions, he directly holds 370,209 shares of Aeluma common stock.
Aeluma, Inc. Chief Executive Officer Jonathan Klamkin reported multiple insider transactions in the company’s common stock. On May 1, 2026, he completed open-market sales totaling 20,000 shares at prices ranging from $23.62 to $26.02 per share, executed under a Rule 10b5-1 trading plan adopted on December 3, 2025.
The filing also shows ten bona fide gifts of common stock totaling 3,133,990 shares between December 19, 2025 and May 1, 2026, including a December 2025 transfer of 1,476,995 shares to a family trust for estate-planning purposes, where Klamkin and his spouse serve as sole trustees. Following these transactions, he continues to hold Aeluma shares directly and through the family trust as reported.
Aeluma, Inc. Chief Executive Officer Jonathan Klamkin sold 20,000 shares of common stock in an open-market transaction on April 1, 2026. The shares were sold at a weighted average price of $13.0975 per share, with individual sale prices ranging from $12.82 to $13.325 per share.
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2025. Following these transactions, Klamkin directly holds 1,409,398 shares of Aeluma common stock.
Aeluma, Inc. Chief Executive Officer Jonathan Klamkin reported open-market sales of a total of 50,000 shares of Aeluma common stock on March 4, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025.
The transactions consisted of 28,206 shares sold at a weighted average price of $17.7746 per share, with individual sale prices ranging from $17.11 to $18.10, and 21,794 shares sold at a weighted average price of $18.4110 per share, with prices ranging from $18.11 to $19.03.
Following these sales, Klamkin directly owned 1,429,398 shares of Aeluma common stock.
ENSLEY CRAIG H reported acquisition or exercise transactions in this Form 4 filing.
Aeluma, Inc. director Craig H. Ensley reported an equity award of 10,633 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share. After this grant, he holds 27,300 shares of common stock. The units are scheduled to vest in stages: about 1/12 on December 31, 2025, 1/4 on March 31, June 30, and September 30, 2026, and 1/6 on November 30, 2026.
Paglia John Kenneth reported acquisition or exercise transactions in this Form 4 filing.
Aeluma, Inc. director John Kenneth Paglia reported receiving a grant of 10,861 shares of common stock in the form of restricted stock units at a stated price of $0 per share. Following this award, he holds 23,361 shares directly. The units are scheduled to vest over time: about 1/12 on December 31, 2025, 1/4 each on March 31, June 30, and September 30, 2026, and 1/6 on November 30, 2026.
Aeluma, Inc. director Byron Michael reported receiving equity-based compensation in the form of common stock and stock options. He was granted 13,343 shares of common stock as restricted stock units that are scheduled to vest over several dates through November 30, 2026. The vesting schedule covers approximately 1/12 of the shares on December 31, 2025, 1/4 of the shares on March 31, June 30, and September 30, 2026, and 1/6 of the shares on November 30, 2026. He also acquired stock options for 3,653 shares that are fully vested as of the grant, giving him the right to buy additional common stock.
Denbaars Steven reported acquisition or exercise transactions in this Form 4 filing.
Aeluma, Inc. director Steven Denbaars reported an equity award of 10,121 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share. Following this grant, his reported direct holdings total 395,209 shares of common stock.
The restricted stock units are scheduled to vest over several dates: approximately one-twelfth of the shares on December 31, 2025, one-quarter of the shares on March 31, June 30, and September 30, 2026, and the remaining one-sixth on November 30, 2026.
Aeluma, Inc. director Steven Denbaars reported selling a total of 25,000 shares of common stock in two open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 20, 2025. He sold 12,500 shares on February 25, 2026 at a weighted average price of $17.5813 per share and 12,500 shares on February 26, 2026 at a weighted average price of $15.8475 per share, with actual sale prices on each day spanning disclosed ranges. After these sales, he continues to hold 385,088 shares directly.
Aeluma, Inc. insider Mark N. Tompkins reported two stock sales and is now a former 10% owner. On February 4, 2026, he sold 28,544 common shares at a weighted average price of $14.63, and another 5,956 shares at a weighted average price of $15.12.
Each reported price reflects multiple trades within disclosed ranges of $13.94–$14.91 and $14.94–$15.50. After these transactions, Tompkins beneficially owned 1,790,488 Aeluma common shares directly and no longer qualifies as a 10% beneficial owner.
Aeluma, Inc. 10% owner Mark N. Tompkins reported multiple open‑market sales of common stock over several days. On 01/29/2026 and 01/30/2026 he sold shares at weighted average prices between $15.45 and $17.33 per share, followed by an additional sale on 02/02/2026 at a weighted average price of $15.74 per share. After these transactions, he directly beneficially owned 1,824,988 Aeluma common shares.
Aeluma, Inc. insider activity: Mark N. Tompkins, a 10% owner of Aeluma (ALMU), reported open‑market sales of a total of 105,000 shares of common stock over three days in January 2026. The trades occurred on January 20–22, 2026 at weighted average prices reported between $18.05 and $21.58 per share, with each price reflecting multiple individual transactions within the stated ranges. After these sales, Tompkins directly beneficially owned 1,919,988 shares of Aeluma common stock. The footnotes state that the reported prices are weighted averages and that more detailed breakdowns by individual execution price are available upon request.
Aeluma, Inc. director Mark N. Tompkins reported open-market sales of Aeluma common stock in mid-December. On December 9, 2025, he sold 10,861 shares at a weighted average price of $16.39 and 19,139 shares at a weighted average price of $17.06. On December 10, 2025, he sold 20,000 shares at a weighted average price of $17.49.
After these transactions, Tompkins beneficially owns 2,169,988 shares of Aeluma common stock directly. Each reported price is a weighted average for multiple individual trades executed within stated price ranges on the respective dates.
Aeluma (ALMU) insider activity: A reporting person disclosed open-market sales of common stock. On 10/17/2025, sales totaled 33,344 shares at a weighted average price of $16.75, 5,913 shares at $17.77, and 743 shares at $18.45. On 10/20/2025, an additional 37,500 shares were sold at $16.39. The prices reflect weighted averages across multiple trades within disclosed ranges.
Following these transactions, the reporting person beneficially owned 2,319,988 shares, held directly. The filer is identified as a Director.
Aeluma, Inc. (ALMU) director reported open‑market sales of common stock on 10/15/2025 and 10/16/2025 (transaction code S). On 10/15/2025, sales included 24,147 shares at $20.11 (weighted average) and 15,853 shares at $21.31. On 10/16/2025, sales included 17,540 shares at $18.97, 6,650 shares at $19.96, and 810 shares at $20.72. Following these trades, the reporting person beneficially owns 2,397,488 shares, held directly. Footnotes note weighted‑average pricing across stated ranges.
Aeluma, Inc. (ALMU) reported insider share sales on a Form 4. The reporting person executed multiple open‑market sales of common stock: 30,587 shares at a weighted average price of $16.60 on 10/10/2025 (range $16.06–$17.05), an additional 4,413 shares at $17.16 on 10/10/2025 (range $17.06–$17.25), 35,031 shares at $16.97 on 10/13/2025 (range $16.53–$17.49), 300 shares at $17.57 on 10/13/2025, and 36,855 shares at $19.86 on 10/14/2025 (range $19.65–$20.32). After these transactions, the reporting person beneficially owned 2,462,488 shares, held directly.